Bauer, Sebastian

[["dc.bibliographiccitation.firstpage","2325"],["dc.bibliographiccitation.issue","15"],["dc.bibliographiccitation.journal","Cancer"],["dc.bibliographiccitation.lastpage","2333"],["dc.bibliographiccitation.volume","120"],["dc.contributor.author","Joensuu, Heikki"],["dc.contributor.author","Eriksson, Mikael"],["dc.contributor.author","Hall, Kirsten Sundby"],["dc.contributor.author","Hartmann, Joerg Thomas"],["dc.contributor.author","Pink, Daniel"],["dc.contributor.author","Schuette, Jochen"],["dc.contributor.author","Ramadori, Giuliano"],["dc.contributor.author","Hohenberger, Peter"],["dc.contributor.author","Duyster, Justus"],["dc.contributor.author","Al-Batran, Salah-Eddin"],["dc.contributor.author","Schlemmer, Marcus"],["dc.contributor.author","Bauer, Sebastian"],["dc.contributor.author","Wardelmann, Eva"],["dc.contributor.author","Sarlomo-Rikala, Maarit"],["dc.contributor.author","Nilsson, Bengt"],["dc.contributor.author","Sihto, Harri"],["dc.contributor.author","Ballman, Karla V."],["dc.contributor.author","Leinonen, Mika"],["dc.contributor.author","DeMatteo, Ronald P."],["dc.contributor.author","Reichardt, Peter"],["dc.date.accessioned","2018-11-07T09:37:08Z"],["dc.date.available","2018-11-07T09:37:08Z"],["dc.date.issued","2014"],["dc.description.abstract","BACKGROUND: Little is known about the factors that predict for gastrointestinal stromal tumor (GIST) recurrence in patients treated with adjuvant imatinib. METHODS: Risk factors for GIST recurrence were identified, and 2 risk stratification scores were developed using the database of the Scandinavian Sarcoma Group (SSG) XVIII trial, where 358 patients with high-risk GIST with no overt metastases were randomly assigned to adjuvant imatinib 400 mg/day either for 12 or 36 months after surgery. The findings were validated in the imatinib arm of the American College of Surgeons Oncology Group Z9001 trial, where 359 patients with GIST were randomized to receive imatinib and 354 were to receive placebo for 12 months. RESULTS: Five factors (high tumor mitotic count, nongastric location, large size, rupture, and adjuvant imatinib for 12 months) were independently associated with unfavorable recurrence-free survival (RFS) in a multivariable analysis in the SSGXVIII cohort. A risk score based on these 5 factors had a concordance index with GIST recurrence of 78.9%. When a simpler score consisting of the 2 strongest predictive factors (mitotic count and tumor site) was devised, the groups with the lowest, intermediate high, and the highest risk had 5-year RFS of 76.7%, 47.5%, and 8.4%, respectively. Both scores were strongly associated with RFS in the validation cohort (P<.001 for each comparison). CONCLUSIONS: The scores generated were effective in stratifying the risk of GIST recurrence in patient populations treated with adjuvant imatinib. Patients with nongastric GIST with a high mitotic count are at a particularly high risk for recurrence. (C) 2014 The Authors. Cancer published by Wiley Periodicals, Inc. on behalf of American Cancer Society. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made."],["dc.identifier.doi","10.1002/cncr.28669"],["dc.identifier.isi","000340241500015"],["dc.identifier.pmid","24737415"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/12825"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/32770"],["dc.notes.intern","Merged from goescholar"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Wiley-blackwell"],["dc.relation.issn","1097-0142"],["dc.relation.issn","0008-543X"],["dc.rights","CC BY-NC-ND 3.0"],["dc.rights.uri","https://creativecommons.org/licenses/by-nc-nd/3.0"],["dc.title","Risk Factors for Gastrointestinal Stromal Tumor Recurrence in Patients Treated With Adjuvant Imatinib"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","1241"],["dc.bibliographiccitation.issue","8"],["dc.bibliographiccitation.journal","JAMA Oncology"],["dc.bibliographiccitation.volume","6"],["dc.contributor.author","Joensuu, Heikki"],["dc.contributor.author","Eriksson, Mikael"],["dc.contributor.author","Sundby Hall, Kirsten"],["dc.contributor.author","Reichardt, Annette"],["dc.contributor.author","Hermes, Barbara"],["dc.contributor.author","Schütte, Jochen"],["dc.contributor.author","Cameron, Silke"],["dc.contributor.author","Hohenberger, Peter"],["dc.contributor.author","Jost, Philipp J."],["dc.contributor.author","Al-Batran, Salah-Eddin"],["dc.contributor.author","Lindner, Lars H."],["dc.contributor.author","Bauer, Sebastian"],["dc.contributor.author","Wardelmann, Eva"],["dc.contributor.author","Nilsson, Bengt"],["dc.contributor.author","Kallio, Raija"],["dc.contributor.author","Jaakkola, Panu"],["dc.contributor.author","Junnila, Jouni"],["dc.contributor.author","Alvegård, Thor"],["dc.contributor.author","Reichardt, Peter"],["dc.date.accessioned","2021-04-14T08:24:59Z"],["dc.date.available","2021-04-14T08:24:59Z"],["dc.date.issued","2020"],["dc.identifier.doi","10.1001/jamaoncol.2020.2091"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/81481"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-399"],["dc.relation.issn","2374-2437"],["dc.title","Survival Outcomes Associated With 3 Years vs 1 Year of Adjuvant Imatinib for Patients With High-Risk Gastrointestinal Stromal Tumors"],["dc.title.alternative","An Analysis of a Randomized Clinical Trial After 10-Year Follow-up"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","128"],["dc.bibliographiccitation.journal","European Journal of Cancer"],["dc.bibliographiccitation.lastpage","133"],["dc.bibliographiccitation.volume","59"],["dc.contributor.author","Eriksson, Mikael"],["dc.contributor.author","Reichardt, Peter"],["dc.contributor.author","Hall, Kirsten Sundby"],["dc.contributor.author","Schutte, Jochen"],["dc.contributor.author","Cameron, Silke"],["dc.contributor.author","Hohenberger, Peter"],["dc.contributor.author","Bauer, Sebastian"],["dc.contributor.author","Leinonen, Mika"],["dc.contributor.author","Reichardt, Annette"],["dc.contributor.author","Davis, Maria Rejmyr"],["dc.contributor.author","Alvegard, Thor"],["dc.contributor.author","Joensuu, Heikki"],["dc.date.accessioned","2018-11-07T10:15:08Z"],["dc.date.available","2018-11-07T10:15:08Z"],["dc.date.issued","2016"],["dc.description.abstract","Purpose: Preoperative percutaneous transabdominal wall biopsy may be considered to diagnose gastrointestinal stromal tumour (GIST) and plan preoperative treatment with tyrosine kinase inhibitors when an endoscopic biopsy is not possible. Hypothetically, a transabdominal wall biopsy might lead to cell seeding and conversion of a local GIST to a disseminated one. We investigated the influence of preoperative needle biopsy on survival outcomes. Methods: We collected the clinical data from hospital case records of the 397 patients who participated in the Scandinavian Sarcoma Group (SSG) XVIII/Arbeitsgemeinschaft Internistische Onkologie (AIO) randomised trial and who had a transabdominal fine needle and/or core needle biopsy carried out prior to study entry. The SSG XVIII/AIO trial compared 1 and 3 years of adjuvant imatinib in a patient population with a high risk of GIST recurrence after macroscopically radical surgery. The primary end-point was recurrence-free survival (RFS), and the secondary end-points included overall survival (OS). Results: A total of 47 (12.0%) out of the 393 patients with data available underwent a percutaneous biopsy. No significant difference in RFS or OS was found between the patients who underwent or did not undergo a percutaneous biopsy either in the entire series or in subpopulation analyses, except for a statistically significant RFS advantage for patients who had a percutaneous biopsy and a tumour >= 10 cm in diameter. Conclusion: A preoperative diagnostic percutaneous biopsy of a suspected GIST may not increase the risk for GIST recurrence in a patient population who receive adjuvant imatinib after the biopsy. (C) 2016 Elsevier Ltd. All rights reserved."],["dc.identifier.doi","10.1016/j.ejca.2016.02.021"],["dc.identifier.isi","000375138200014"],["dc.identifier.pmid","27033260"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/40752"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Elsevier Sci Ltd"],["dc.relation.issn","1879-0852"],["dc.relation.issn","0959-8049"],["dc.title","Needle biopsy through the abdominal wall for the diagnosis of gastrointestinal stromal tumour - Does it increase the risk for tumour cell seeding and recurrence?"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","602"],["dc.bibliographiccitation.issue","5"],["dc.bibliographiccitation.journal","JAMA ONCOLOGY"],["dc.bibliographiccitation.lastpage","609"],["dc.bibliographiccitation.volume","3"],["dc.contributor.author","Joensuu, Heikki"],["dc.contributor.author","Wardelmann, Eva"],["dc.contributor.author","Sihto, Harri"],["dc.contributor.author","Eriksson, Mikael"],["dc.contributor.author","Hall, Kirsten Sundby"],["dc.contributor.author","Reichardt, Annette"],["dc.contributor.author","Hartmann, Joerg Thomas"],["dc.contributor.author","Pink, Daniel"],["dc.contributor.author","Cameron, Silke"],["dc.contributor.author","Hohenberger, Peter"],["dc.contributor.author","Al-Batran, Salah-Eddin"],["dc.contributor.author","Schlemmer, Marcus"],["dc.contributor.author","Bauer, Sebastian"],["dc.contributor.author","Nilsson, Bengt"],["dc.contributor.author","Kallio, Raija"],["dc.contributor.author","Junnila, Jouni"],["dc.contributor.author","Vehtari, Aki"],["dc.contributor.author","Reichardt, Peter"],["dc.date.accessioned","2018-11-07T10:24:18Z"],["dc.date.available","2018-11-07T10:24:18Z"],["dc.date.issued","2017"],["dc.description.abstract","IMPORTANCE Little is known about whether the duration of adjuvant imatinib influences the prognostic significance of KIT proto-oncogene receptor tyrosine kinase (KIT) and platelet-derived growth factor receptor a (PDGFRA) mutations. OBJECTIVE To investigate the effect of KIT and PDGFRA mutations on recurrence-free survival (RFS) in patients with gastrointestinal stromal tumors (GISTs) treated with surgery and adjuvant imatinib. DESIGN, SETTING, AND PARTICIPANTS This exploratory study is based on the Scandinavian Sarcoma Group VIII/Arbeitsgemeinschaft Internistische Onkologie (SSGXVIII/AIO) multicenter clinical trial. Between February 4, 2004, and September 29, 2008, 400 patients who had undergone surgery for GISTs with a high risk of recurrence were randomized to receive adjuvant imatinib for 1 or 3 years. Of the 397 patients who provided consent, 341 (85.9%) had centrally confirmed, localized GISTs with mutation analysis for KIT and PDGFRA performed centrally using conventional sequencing. During a median follow-up of 88 months (completed December 31, 2013), 142 patients had GIST recurrence. Data of the evaluable population were analyzed February 4, 2004, through December 31, 2013. MAIN OUTCOMES AND MEASURES The main outcome was RFS. Mutations were grouped by the gene and exon. KIT exon 11 mutations were further grouped as deletion or insertion-deletion mutations, substitution mutations, insertion or duplication mutations, and mutations that involved codons 557 and/or 558. RESULTS Of the 341 patients (175 men and 166women; median age at study entry, 62 years) in the 1-year group and 60 years in the 3-year group), 274 (80.4%) had GISTs with a KIT mutation, 43 (12.6%) had GISTs that harbored a PDGFRA mutation, and 24 (7.0%) had GISTs thatwere wild type for these genes. PDGFRA mutations and KIT exon 11 insertion or duplication mutations were associated with favorable RFS, whereas KIT exon 9 mutations were associated with unfavorable outcome. Patients with KIT exon 11 deletion or insertion-deletion mutation had better RFS when allocated to the 3-year group compared with the 1-year group (5-year RFS, 71.0% vs 41.3%; P<.001), whereas no significant benefit from the 3-year treatment was found in the other mutational subgroups examined. KIT exon 11 deletion mutations, deletions that involved codons 557 and/or 558, and deletions that led to pTrp557_Lys558delwere associated with poor RFS in the 1-year group but not in the 3-year group. Similarly, in the subset with KIT exon 11 deletion mutations, higher-than-the-median mitotic counts were associated with unfavorable RFS in the 1-year group but not in the 3-year group. CONCLUSIONS AND RELEVANCE Patients with KIT exon 11 deletion mutations benefit most from the longer duration of adjuvant imatinib. The duration of adjuvant imatinib modifies the risk of GIST recurrence associated with some KIT mutations, including deletions that affect exon 11 codons 557 and/or 558."],["dc.identifier.doi","10.1001/jamaoncol.2016.5751"],["dc.identifier.isi","000401114700006"],["dc.identifier.pmid","28334365"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/42630"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","PUB_WoS_Import"],["dc.publisher","Amer Medical Assoc"],["dc.relation.issn","2374-2445"],["dc.relation.issn","2374-2437"],["dc.title","Effect of KIT and PDGFRA Mutations on Survival in Patients With Gastrointestinal Stromal Tumors Treated With Adjuvant Imatinib An Exploratory Analysis of a Randomized Clinical Trial"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","244"],["dc.bibliographiccitation.issue","3"],["dc.bibliographiccitation.journal","Journal of Clinical Oncology"],["dc.bibliographiccitation.lastpage","250"],["dc.bibliographiccitation.volume","34"],["dc.contributor.author","Joensuu, Heikki"],["dc.contributor.author","Eriksson, Mikael"],["dc.contributor.author","Sundby Hall, Kirsten"],["dc.contributor.author","Reichardt, Annette"],["dc.contributor.author","Hartmann, Jörg T."],["dc.contributor.author","Pink, Daniel"],["dc.contributor.author","Ramadori, Giuliano"],["dc.contributor.author","Hohenberger, Peter"],["dc.contributor.author","Al-Batran, Salah-Eddin"],["dc.contributor.author","Schlemmer, Marcus"],["dc.contributor.author","Bauer, Sebastian"],["dc.contributor.author","Wardelmann, Eva"],["dc.contributor.author","Nilsson, Bengt"],["dc.contributor.author","Sihto, Harri"],["dc.contributor.author","Bono, Petri"],["dc.contributor.author","Kallio, Raija"],["dc.contributor.author","Junnila, Jouni"],["dc.contributor.author","Alvegård, Thor"],["dc.contributor.author","Reichardt, Peter"],["dc.date.accessioned","2020-12-10T18:41:29Z"],["dc.date.available","2020-12-10T18:41:29Z"],["dc.date.issued","2016"],["dc.description.abstract","Purpose Three years of adjuvant imatinib therapy are recommended for patients with GI stromal tumor (GIST) with high-risk features, according to survival findings in the Scandinavian Sarcoma Group XVIII/AIO (Arbeitsgemeinschaft Internistische Onkologie) trial. To investigate whether the survival benefits have persisted, we performed the second planned analysis of the trial. Patients and Methods Eligible patients had macroscopically completely excised, KIT-positive GIST with a high risk of recurrence, as determined by using the modified National Institutes of Health criteria. After surgery, the patients were randomly assigned to receive imatinib for either 1 or 3 years. The primary objective was recurrence-free survival (RFS), and the secondary objectives included survival. Results A total of 400 patients were entered onto this open-label study between February 4, 2004, and September 29, 2008. During a median follow-up of 90 months, 171 recurrences and 69 deaths were detected. Patients assigned to the 3-year group had longer RFS than those assigned to the 1-year group; 5-year RFS was 71.1% versus 52.3%, respectively (hazard ratio [HR], 0.60; 95% CI 0.44 to 0.81; P < .001), and survival was 91.9% versus 85.3% (HR, 0.60; 95% CI, 0.37 to 0.97; P = .036). Patients in the 3-year group survived longer in the subset with centrally confirmed GIST and without macroscopic metastases at study entry (93.4% v 86.8%; HR, 0.53; 95% CI, 0.30 to 0.93; P - .024). Similar numbers of cardiac events and second cancers were recorded in the groups. Conclusion Three years of adjuvant imatinib therapy results in longer survival than 1 year of imatinib. High 5-year survival rates are achievable in patient populations with high-risk GIST. (C) 2015 by American Society of Clinical Oncology"],["dc.identifier.doi","10.1200/JCO.2015.62.9170"],["dc.identifier.eissn","1527-7755"],["dc.identifier.isi","000374331100012"],["dc.identifier.issn","0732-183X"],["dc.identifier.pmid","26527782"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/77593"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-354"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Amer Soc Clinical Oncology"],["dc.relation.issn","1527-7755"],["dc.relation.issn","0732-183X"],["dc.title","Adjuvant Imatinib for High-Risk GI Stromal Tumor: Analysis of a Randomized Trial"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","1265"],["dc.bibliographiccitation.issue","12"],["dc.bibliographiccitation.journal","JAMA"],["dc.bibliographiccitation.lastpage","1272"],["dc.bibliographiccitation.volume","307"],["dc.contributor.author","Joensuu, Heikki"],["dc.contributor.author","Eriksson, Mikael"],["dc.contributor.author","Hall, Kirsten Sundby"],["dc.contributor.author","Hartmann, Joerg Thomas"],["dc.contributor.author","Pink, Daniel"],["dc.contributor.author","Schuette, Jochen"],["dc.contributor.author","Ramadori, Giuliano"],["dc.contributor.author","Hohenberger, Peter"],["dc.contributor.author","Duyster, Justus"],["dc.contributor.author","Al-Batran, Salah-Eddin"],["dc.contributor.author","Schlemmer, Marcus"],["dc.contributor.author","Bauer, Sebastian"],["dc.contributor.author","Wardelmann, Eva"],["dc.contributor.author","Sarlomo-Rikala, Maarit"],["dc.contributor.author","Nilsson, Bengt"],["dc.contributor.author","Sihto, Harri"],["dc.contributor.author","Monge, Odd R."],["dc.contributor.author","Bono, Petri"],["dc.contributor.author","Kallio, Raija"],["dc.contributor.author","Vehtari, Aki"],["dc.contributor.author","Leinonen, Mika"],["dc.contributor.author","Alvegard, Thor"],["dc.contributor.author","Reichardt, Peter"],["dc.date.accessioned","2018-11-07T09:12:09Z"],["dc.date.available","2018-11-07T09:12:09Z"],["dc.date.issued","2012"],["dc.description.abstract","Context Adjuvant imatinib administered for 12 months after surgery has improved recurrence-free survival (RFS) of patients with operable gastrointestinal stromal tumor (GIST) compared with placebo. Objective To investigate the role of imatinib administration duration as adjuvant treatment of patients who have a high estimated risk for GIST recurrence after surgery. Design, Setting, and Patients Patients with KIT-positive GIST removed at surgery were entered between February 2004 and September 2008 to this randomized, open-label phase 3 study conducted in 24 hospitals in Finland, Germany, Norway, and Sweden. The risk of GIST recurrence was estimated using the modified National Institutes of Health Consensus Criteria. Intervention Imatinib, 400 mg per day, orally for either 12 months or 36 months, started within 12 weeks of surgery. Main Outcome Measures The primary end point was RFS; the secondary end points included overall survival and treatment safety. Results Two hundred patients were allocated to each group. The median follow-up time after randomization was 54 months in December 2010. Diagnosis of GIST was confirmed in 382 of 397 patients (96%) in the intention-to-treat population at a central pathology review. KIT or PDGFRA mutation was detected in 333 of 366 tumors (91%) available for testing. Patients assigned for 36 months of imatinib had longer RFS compared with those assigned for 12 months (hazard ratio [HR], 0.46; 95% CI, 0.32-0.65; P = .001; 5-year RFS, 65.6% vs 47.9%, respectively) and longer overall survival (HR, 0.45; 95% CI, 0.22-0.89; P=. 02; 5-year survival, 92.0% vs 81.7%). Imatinib was generally well tolerated, but 12.6% and 25.8% of patients assigned to the 12-and 36-month groups, respectively, discontinued imatinib for a reason other than GIST recurrence. Conclusion Compared with 12 months of adjuvant imatinib, 36 months of imatinib improved RFS and overall survival of GIST patients with a high risk of GIST recurrence."],["dc.identifier.doi","10.1001/jama.2012.347"],["dc.identifier.isi","000301978400022"],["dc.identifier.pmid","22453568"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/26884"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Amer Medical Assoc"],["dc.relation.issn","1538-3598"],["dc.relation.issn","0098-7484"],["dc.title","One vs Three Years of Adjuvant Imatinib for Operable Gastrointestinal Stromal Tumor A Randomized Trial"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]